Zydus Lifesciences Limited has secured final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ketoconazole Shampoo, 2% (a generic version of Nizoral® Shampoo, 2%).
What is Ketoconazole Shampoo?
Ketoconazole shampoo is a medicated antifungal treatment designed to combat dandruff, fungal infections, and other scalp conditions. It helps reduce itching, flaking, and irritation caused by fungal overgrowth.
Manufacturing & Market Potential
Zydus will manufacture Ketoconazole Shampoo, 2% at its topical manufacturing facility in Changodar, Ahmedabad. The product holds significant market value, with annual sales reaching $68.89 million in the United States (IQVIA MAT January 2025).
Zydus’ Growing US Market Presence
With this latest approval, Zydus now has 418 approvals and has filed 483 Abbreviated New Drug Applications (ANDAs) since FY 2003-04. This milestone further strengthens the company’s position in the U.S. pharmaceutical market, reinforcing its commitment to providing affordable, high-quality generic medicines.
In the meantime, Zydus Lifesciences’ shares opened today at ₹900.80, reaching a high of ₹905.20 and a low of ₹894.00. The stock remains volatile, trading near its 52-week low of ₹855.10, while the 52-week high stands at ₹1,324.30.
